19301-39-4

Usage

Uses

Benzo[b]thiophen-6-ol is used as a building block in organic synthesis.

InChI:InChI=1/C8H6OS/c9-7-2-1-6-3-4-10-8(6)5-7/h1-5,9H

Upstream product

• 90560-10-4 6-methoxy-benzo[b]thiophene 
• 5339-33-3 6-aminobenzothiophene 
• 82194-65-8 6-acetoxybenzothiophen 
• 95-15-8 Benzo[b]thiophene 
• 22546-89-0 6-methoxy-benzothiophene-3-ol 
• 3996-32-5 [(3-methoxyphenyl)sulfanyl]acetic acid 
• 29957-59-3 boron tribromide-dimethyl sulfide complex 
• 331-64-6 2-fluoro-4-methoxy-benzaldehyde 
• 187753-62-4 ethyl 6-methoxybenzo[b]thiophene-2-carboxylate 
• 102539-79-7 6-methoxybenzo[b]thiophene-2-carboxylic acid 

Downstream Products

• 108238-95-5 benzoic acid benzo[b]thiophen-6-yl ester 
• 343929-61-3 6-hydroxy-2,3-dihydrobenzo[b]thiophene 
• 82194-87-4 2-p-Tolyl-2,3-dihydro-benzo[b]thiophen-6-ol 
• 82194-94-3 3-p-Tolyl-2,3-dihydro-benzo[b]thiophen-6-ol 
• 82194-98-7 4,5-dihydro-2,4-di-p-tolylbenzothiophen-7(6H)-one 
• 82194-86-3 2-Phenyl-2,3-dihydro-benzo[b]thiophen-6-ol 
• 82194-93-2 3-Phenyl-2,3-dihydro-benzo[b]thiophen-6-ol 
• 82194-75-0 4,5-dihydro-2,4-diphenylbenzothiophen-7(6H)-one 
• 648906-10-9 2-(4-methanesulfonyl-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thiophen-6-ol 
• 648906-02-9 6-benzyloxy-2,3-dibromo-benzo[b]thiophene 
• 648906-03-0 6-benzyloxy-2,3-dibromo-benzo[b]thiophene 1-oxide 
• 648906-04-1 1-{2-[4-(6-benzyloxy-2-bromo-1-oxo-1H-1λ⁴-benzo[b]thiophen-3-yloxy)-phenoxy]-ethyl}-piperidine 
• 648905-98-0 1-{2-[4-(6-benzyloxy-2-bromo-benzo[b]thiophen-3-yloxy)-phenoxy]-ethyl}-piperidine 
• 946077-41-4 C₃₇H₃₉NO₃S 

Relevant academic research and scientific papers

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

NOVEL INHIBITORS OF BETA-LACTAMASE

This invention provides novel β-lactamase inhibitors of the aryl- and heteroarylsulfonamidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammonium groups. The compounds inhibit three classes of β-lactamases and synergize the antibacterial effects of β-lactam antibiotics (e.g., imipenem and ceftazidime) against those micro-organisms normally resistant to the β-lactam antibiotics as a result of the presence of the β-lactamases. Formula (I) or pharmaceutically acceptable salt thereof.

2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT

2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: wherein R1-R4, V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight β-amyloid peptide binding compound, generation of malignant high-molecular weight β-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.

FUSED HETEROCYCLIC COMPOUND

The present invention provides a fused heterocyclic compound having a tyrosine kinase inhibitory action, which is represented by the formula: wherein R1 is a hydrogen atom, a halogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom; R2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to each other to form an optionally substituted ring structure; R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to the carbon atom on ring A to form an optionally substituted ring structure; ring A is an optionally substituted benzene ring; and ring B is (i) an optionally substituted fused ring, or (ii) a pyridine ring having optionally substituted carbamoyl (the pyridine ring is optionally further substituted).

9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS

The present invention relates to a 9-azabicyclo[3.3.1]nonane derivative of formula (I), wherein R1 is H or C1-5alkyl; X is O or NR2, wherein R2 is H, C1-5alkyl or C2-5acyl and Ar is C6-10aryl or a 5-10 membered heteroaryl ring system, both being optionally substituted with one to three of R3-R5 independently selected from halogen, C1-5alkyl, C1-5alkoxy, C3-6cycloalkyl, C2-5alkenyl, C2-5alkynyl, CN, NO2, hydroxy, phenyl, phenoxy and phenylC1-2alkoxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein said phenyl, phenoxy and phenylC1-2alkoxy are optionally substituted with one to three substituents independently selected from halogen and methyl or two of R3-R5 at adjacent positions together form a methylenedioxy or propylene unit, with the proviso that the compounds exo-9-methyl-3-phenoxy-9-azabicyclo[3.3.1]nonane and N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H indazole-5-amine are excluded, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 9-azabicyclo[3.3.1]nonane derivatives and to their use in therapy.

9-Azabicyclo[3.3.1]nonane derivatives

The present invention relates to a 9-azabicyclo[3.3.1]nonane derivative of formula I, wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 9-azabicyclo[3.3.1]nonane derivatives and to their use in therapy.

Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety

Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation.

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R14; with R1, R2, R3, R4, R5, R6, R7, R8, and R14 defined herein.

SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP

The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

Addition Reactions of Benzothiophen. Part 4. Reactions of Some Acetoxy- and Hydroxy-benzothiophens with Benzene or Toluene

Heating acetoxybenzothiophens with AlCl3-benzene can give the normal Fries-rearranged products (for the 4-OAc and 7-OAc isomers); these sometimes react further to give their 2,3-dihydro- (for 4-OAc and 7-OAc) or 2-phenyl derivatives (for 6-OAc).Alternatively, benzene can add across the 2,3-double bond of the acetoxy-compound, to give the 2- (for 6-OAc) or 3-phenyl-2,3-dihydrobenzothiophens (for 7-Oac).With AlCl3 in dichloromethane, 6-acetoxybenzothiophen undergoes intermolecular transfer of an acetyl group to give a mixture of 6-acetoxy-2- and 3-acetylbenzothiophens and 6-hydroxybenzothiophen.With AlCl3 in benzene at room temperature, 4-acetoxybenzothiophen gives a rearranged product, 4,5-dihydro-2,4-diphenylbenzothiophen-7(6H)-one (3a) (17percent).In the presence of AlCl3 for 0.5 h, 4-, 5-, 6-, and 7-hydroxybenzothiophens undergo addition of benzene or toluene, to give the appropriate 2-aryl-2,3-dihydrohydroxybenzothiophens (1).Yields are high for the 4- and 6-hydroxy-isomers (80-85percent), but lower for the 5- (55percent) and 7-isomers (10percent).In each of these reactions the starting hydroxybenzothiophen is partly converted into its 2,3-dihydro-derivative. 5- and 7-Hydroxybenzothiophen also each give the same 4,5-dihydro-2,4-diarylbenzothiophen-7(6H)-one (3) (25percent) in this reaction.When the reaction period with benzene or toluene is extended to 5 days, the amount of solvent addition product (1) decreases, but all four hydroxy-isomers now give the same rearranged product (3).The mechanism of this unusual rearrangement is discussed in terms of a spiro-intermediate.